(Q40436905)

20 September 2017

1 reference

title

Management of early nephropathy in diabetic patients (English)

1 reference

20 September 2017

C. E. Mogensen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7598486

5 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7598486

5 June 2024

publication date

1 January 1995

1 reference

full work available at URL

20 September 2017

https://www.annualreviews.org/doi/pdf/10.1146/annurev.med.46.1.79

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Annual Review of Medicine

5 June 2024

published in

1 reference

20 September 2017

volume

46

1 reference

20 September 2017

page(s)

79-93

1 reference

Early diabetic nephropathy. Emerging treatment options

20 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

5 June 2024

2

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Monitoring diabetic nephropathy: glomerular filtration rate and abnormal albuminuria in diabetic renal disease--reproducibility, progression, and efficacy of antihypertensive intervention.

5 June 2024

3

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes

5 June 2024

4

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?

5 June 2024

5

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

5 June 2024

6

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.

5 June 2024

8

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Epidemiology of microalbuminuria in diabetes and in the background population.

5 June 2024

9

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Microalbuminuria Collaborative Study Group, United Kingdom

5 June 2024

12

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer's and Lewy body type dementia

5 June 2024

15

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Increased glomerular filtration rate as a predictor of diabetic nephropathy--an 8-year prospective study

5 June 2024

16

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study

5 June 2024

18

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Scientific and ethical consequences of disease prediction

5 June 2024

19

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment

5 June 2024

20

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy

5 June 2024

22

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria

5 June 2024

26

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies.

5 June 2024

29

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Effect of antihypertensive treatment on progression of incipient diabetic nephropathy

5 June 2024

30

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.

5 June 2024

31

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group

5 June 2024

32

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Treatment of hypertension in diabetes

5 June 2024

35

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy

5 June 2024

37

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

5 June 2024

38

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis

5 June 2024

39

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis

5 June 2024

40

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

5 June 2024

41

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells

5 June 2024

42

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients

5 June 2024

43

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?

5 June 2024

44

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

Renoprotective role of ACE inhibitors in diabetic nephropathy

5 June 2024

45

1 reference

https://api.crossref.org/works/10.1146/ANNUREV.MED.46.1.79

5 June 2024

Identifiers

1 reference

20 September 2017

1 reference